Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Merck, Medarex, And Massachusetts In Deal
by Ann M. Thayer
April 27, 2009
| A version of this story appeared in
Volume 87, Issue 17
Merck & Co. has licensed technology developed by biotechnology firm Medarex and the Massachusetts Biologic Laboratories at the University of Massachusetts Medical School for fighting infectious diarrhea. Paying $60 million upfront, Merck will get rights to CDA-1 and CDB-1, a fully human monoclonal antibody duo designed to neutralize the bacterial A and B toxins in Clostridium difficile infections. Medarex and MBL could split another $165 million in milestone payments as well as royalties from product sales by Merck. The antibody combination has completed Phase II clinical trials.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X